Description
Ticagrelor is a reversible oral antiplatelet medication used to reduce the risk of thrombotic cardiovascular events such as heart attacks or strokes. Unlike older agents like clopidogrel, Ticagrelor acts directly and does not require metabolic activation. It provides more rapid and consistent platelet inhibition and is often prescribed alongside low-dose aspirin for dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
Mechanism of Action:
Ticagrelor selectively and reversibly inhibits the P2Y₁₂ adenosine diphosphate (ADP) receptor on platelet surfaces. This prevents ADP-mediated platelet activation and aggregation, thereby reducing clot formation. Its reversible binding offers a faster offset of action compared to irreversible inhibitors like clopidogrel.
Uses:
- Acute Coronary Syndrome (ACS) – including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI)
- Secondary prevention of atherothrombotic events in patients with a history of MI
- Often used in combination with aspirin (dual antiplatelet therapy)
